TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06544590
Drug: Betahistine Mesylate tablet
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study: NCT00168298
Drug: 700 µg Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Study: NCT00369356
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bare metal stenting with administration of oral prednisone as described in the protocol
Study: NCT01422291
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gr
Study: NCT01422291
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1mg/kg intravenous in 100 ml serum physiologic
Study: NCT01422291
Drug: Dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg
Study: NCT00168298
Drug: 350 µg Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.
Study: NCT01662895
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Study: NCT01415427
Drug: BMN 110 - Weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Study: NCT01415427
Drug: BMN 110 - Every Other Week
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Study: NCT01797900
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
Study: NCT01797900
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
Study: NCT02973737
Drug: pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily
Study: NCT03824808
Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
Study: NCT03824808
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
Study: NCT00586495
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
Study: NCT00705783
Drug: Aripiprazole depot
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Study: NCT04049045
Drug: Empagliflozin 25 mg
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Study: NCT00579813
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Study: NCT00454493
Drug: Omacor (omega-3-acid ethyl esters)
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02432235
Drug: Camidanlumab tesirine
Normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT00401752
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401752
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00522587
Drug: Fixed sevoflurane dose 1
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 1 of sevoflurane
Study: NCT00522587
Drug: Fixed sevoflurane dose 2
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 2 of sevoflurane
Study: NCT00522587
Drug: Fixed sevoflurane dose 3
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 3 of sevoflurane
Study: NCT00522587
Drug: Fixed sevoflurane dose 4
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 4 of sevoflurane
Study: NCT01791751
Drug: Clomifene Citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg daily for 5 days
Study: NCT00522587
Drug: Fixed sevoflurane dose 5
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 5 of sevoflurane
Study: NCT00522587
Drug: Fixed sevoflurane dose 6
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 6 of sevoflurane
Study: NCT00084201
Drug: Cranberry juice
Normalized name: cranberry juice
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00084201
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01888042
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg (1 tablet of 10 mg)
Study: NCT01923129
Drug: Prazosin given 6 hours prior to catheter removal in the 24 hour group
Normalized name: prazosin 6 MG
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
Study: NCT04538794
Drug: CDX-0159
Normalized name: Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide wi
DrugBank: Barzolvolimab (DB18934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03106623
Drug: ONO-8577
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of ONO-8577 once a daily for 4 weeks
Study: NCT03106623
Drug: solifenacin succinate + mirabegron
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
Study: NCT03596567
Drug: Glasdegib single 100 mg dose in normal healthy subjects
Normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study: NCT03596567
Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
Normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study: NCT03596567
Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
Normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study: NCT03273153
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
Study: NCT03273153
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 840 mg as IV infusion once in every 2 weeks.
Study: NCT03273153
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
Study: NCT02115204
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02115204
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02115204
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01937234
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses.
Study: NCT04453046
Drug: Pembrolizumab 200mg IV
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
Study: NCT03017170
Drug: Dried Cranberry
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit.
Study: NCT00796276
Drug: IR OROS paliperidone and ER OROS paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01066598
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
Study: NCT01838681
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
Study: NCT00298415
Drug: Paclitaxel + Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
Study: NCT00298415
Drug: Monotherapy (gemcitabine or vinorelbine)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
Study: NCT02067611
Drug: X0002
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parallel Assignment
Study: NCT00376285
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03693677
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
Study: NCT03693677
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
Study: NCT03655080
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes
Study: NCT04339062
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab: via IV, flat predetermined dosage every 21 days.
Study: NCT04339062
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
Study: NCT04339062
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
Study: NCT04339062
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
Study: NCT03155620
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03155620
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03155620
Drug: Larotrectinib Sulfate
Normalized name: Larotrectinib sulfate
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO or via nasogastric- or gastric-tube
Study: NCT03155620
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03155620
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03155620
Drug: Samotolisib
Normalized name: Samotolisib
DrugBank: LY-3023414 (DB12167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03155620
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03897621
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
Study: NCT00191750
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03155620
Drug: Selumetinib Sulfate
Normalized name: selumetinib sulfate
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03155620
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03155620
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or via nasogastric or gastric tube
Study: NCT03155620
Drug: Ulixertinib
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive PO
Study: NCT03155620
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00778882
Drug: VM106
Normalized name: Valsartan and Metoprolol
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Autologous hematopoietic stem cells with MT-gp91 retroviral vector
Study: NCT04663204
Drug: Sparsentan
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose of 400 mg daily
Study: NCT00242827
Drug: Oral CEP-701
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00058955
Drug: sodium oxybate, triazolam and pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium oxybate, triazolam and pentobarbital
Study: NCT00873639
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Study: NCT00873639
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Study: NCT02417298
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
Study: NCT02233985
Drug: 0.9% Sodium Chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Study: NCT02233985
Drug: 3% Sodium Chloride
Normalized name: Dextrose 5% and 0.3% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules 80mg
Normalized name: lipase
DrugBank: Metacavir (DB19084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules 80mg
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules 160mg
Normalized name: lipase
DrugBank: Metacavir (DB19084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules 160mg
Study: NCT00285727
Drug: Ropinirole CR
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03757910
Drug: 11C-PIB
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules 320mg
Normalized name: lipase
DrugBank: Metacavir (DB19084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules 320mg
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 240mg
Normalized name: dimethyl fumarate
DrugBank: Metacavir (DB19084)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules Placebo 240mg
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 160mg
Normalized name: lipase
DrugBank: Metacavir (DB19084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules Placebo 160mg
Study: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 320mg
Normalized name: lipase
DrugBank: Metacavir (DB19084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacavir Enteric-coated Capsules Placebo 320mg
Study: NCT02965859
Drug: Adefovir Dipivoxil Capsule10mg
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir Dipivoxil Capsule10mg
Study: NCT02965859
Drug: Adefovir Dipivoxil Capsule Placebo 10mg
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir Dipivoxil Capsule Placebo 10mg
Study: NCT01606111
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
Study: NCT03257865
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
Study: NCT02342015
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg/day for three months
Study: NCT00399165
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone 400 mg orally for 28 days
Study: NCT00399165
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone 800 mg orally for 28 days
Study: NCT00399165
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dutasteride 0.5 mg orally, once daily for 28 days
Study: NCT00399165
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24.5 mg po once (Day 0)
Study: NCT00428532
Drug: Licorice root extract or Pomegranate juice
Normalized name: pomegranate juice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no